What Timberlyne Therapeutics does

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company founded in 2024 and headquartered in San Diego, California. The company focuses on developing and commercializing transformational therapies for autoimmune diseases, with a stated mission of bringing life-changing medicines to patients with significant unmet medical need. Timberlyne operates with a lean team of 11-50 employees and pursues a capital-efficient asset-acquisition model, leveraging its team's drug development expertise to in-license best-in-class assets targeting compelling biological mechanisms and applying them to disease areas with significant unmet need.

The company's lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity (CDC) that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 is designed to modulate multiple arms of the immune system, with the company claiming potential for both rapid and durable responses across a range of autoimmune diseases. CM313 has been clinically tested in Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of additional autoimmune indications.

Timberlyne is pre-revenue and has not yet commercialized any product. Its revenue model is expected to depend on successful clinical development and regulatory approval of CM313 and future pipeline programs, with commercialization planned upon approval. The company has not disclosed pricing, distribution channels, or marketing infrastructure, consistent with its pre-commercial stage. As of January 2025, Timberlyne raised $180 million in a financing round co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from 3H Health Investment, Boyu Capital, Braidwell, and Lilly Asia Ventures. Daniel Curran serves as Chief Executive Officer and Christian Fougner as VP of Business Operations and Co-Founder.

Name

Timberlyne Therapeutics

Legal name

Timberlyne Therapeutics

Website

https://timberlyne-tx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an anti-CD38 IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity, for autoimmune diseases including ITP, SLE, and multiple myeloma.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Autoimmune Disease Therapeutics

NAICS

Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

Keywords

• Biopharmaceutical therapeutics
• Monoclonal antibody development
• Autoimmune disease treatments
• Clinical-stage immunology
• CD38 targeted therapy

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing transformational therapies for autoimmune diseases. Revenue model will depend on successful clinical development and regulatory approval of CM313 and future pipeline programs.

Go-to-market motion1 record

Core offering

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38 on plasma cells, NK cells, and other immune cells. The asset is being advanced across multiple autoimmune indications, including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, with the goal of bringing life-changing medicines to patients with high unmet need.

Product overview

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company with a single lead product, CM313. CM313 is an IgG1 monoclonal antibody targeting CD38, developed for the treatment of autoimmune diseases. The company plans to develop CM313 across a broad range of autoimmune indications including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.

Differentiator

Problem solved

Functional benefit

Products and services

• CM313 CM313 is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. It is being developed to modulate multiple arms of the immune system and produce both rapid and durable responses across autoimmune indications. CM313 has been tested in Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of autoimmune indications.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights5 records

Direct peers

• Argenx: Commercial-stage biotech developing antibody therapeutics for autoimmune diseases, including FcRn antagonist efgartigimod (Vyvgart). Operates in the same autoimmune biologics space as Timberlyne with a similar asset-acquisition and development approach and overlapping indication strategy.
• MorphoSys: Biotech originally involved in co-development of isatuximab (CD38 antibody) and known for antibody therapeutic development in hematology and autoimmune diseases. Relevant peer given its CD38 antibody heritage and focus on antibody-based autoimmune therapies.
• Sanofi: Commercializes isatuximab (Sarclisa), a CD38-targeting monoclonal antibody approved for multiple myeloma. Competes head-to-head with Timberlyne in the CD38 antibody class with significantly greater resources and global commercial reach.
• Immunovant: Clinical-stage biotech developing antibody therapies for autoimmune diseases, including FcRn-targeting candidates. Comparable as a focused autoimmune antibody developer with similar capital structure and clinical-stage profile to Timberlyne.
• Janssen (Johnson & Johnson): Developer of daratumumab (Darzalex), the leading CD38-targeting monoclonal antibody approved for multiple myeloma and being expanded into autoimmune indications. Directly competes with Timberlyne's CM313 in the same molecular target and overlapping disease areas.

Broad incumbents

• UCB: Global biopharmaceutical company specializing in immunology and neurology, with approved autoimmune biologics (e.g., Cimzia, Rystiggo). Comparable as a focused autoimmune biologics developer and likely competitor for autoimmune market share.
• Takeda Pharmaceutical: Global biopharmaceutical company with a significant rare disease and autoimmune portfolio, including plasma-cell directed therapies. Comparable as a potential competitor or strategic acquirer in autoimmune indications.
• Bristol Myers Squibb: Large biopharmaceutical company with a deep autoimmune disease franchise (e.g., Zeposia, Sotyktu) and significant resources for in-licensing or developing competing CD38 antibodies in autoimmune indications.

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and autoimmune diseases. Comparable as a clinical-stage immunology-focused developer pursuing differentiated mechanisms in the autoimmune space.
• Cabaletta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases, with overlapping indications such as SLE. Comparable as a clinical-stage autoimmune-focused biotech competing for similar patient populations and investor capital.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/TimberlyneTx
• LinkedInlinkedin.com/company/timberlyne-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Timberlyne Therapeutics